Cyclacel Pharmaceuticals, Inc.

Cyclacel Pharmaceuticals, Inc.verified

CYCC

Price:

$0.3176

Market Cap:

$2.00M

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, wh...[Read more]

Industry

Biotechnology

IPO Date

2004-03-16

Stock Exchange

NASDAQ

Ticker

CYCC

The ROE as of December 2024 (TTM) for Cyclacel Pharmaceuticals, Inc. (CYCC) is 2.92%

According to Cyclacel Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current ROE is 2.92%. This represents a change of -1202.65% compared to the average of -265.16% of the last 4 quarters.

Cyclacel Pharmaceuticals, Inc. (CYCC) Historical ROE (quarterly & annually)

How has CYCC ROE performed in the past?

The mean historical ROE of Cyclacel Pharmaceuticals, Inc. over the last ten years is -432.57%. The current 2.92% ROE has changed -775.92% with respect to the historical average. Over the past ten years (40 quarters), CYCC's ROE was at its highest in in the March 2024 quarter at 133.54%. The ROE was at its lowest in in the December 2023 quarter at -868.37%.

Quarterly (TTM)
Annual

Average

-432.57%

Median

-71.53%

Minimum

-3715.82%

Maximum

-25.39%

Cyclacel Pharmaceuticals, Inc. (CYCC) ROE by Quarter and Year

Discovering the peaks and valleys of Cyclacel Pharmaceuticals, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 2.62%

Maximum Annual ROE = -25.39%

Minimum Annual Increase = -62.06%

Minimum Annual ROE = -3715.82%

Quarterly (TTM)
Annual
YearROEChange
2023-3715.82%2.62%
2022-136.68%169.67%
2021-50.69%99.62%
2020-25.39%-62.06%
2019-66.92%40.24%
2018-47.72%39.05%
2017-34.32%-58.46%
2016-82.61%8.49%
2015-76.15%-14.82%
2014-89.39%146.72%

Cyclacel Pharmaceuticals, Inc. (CYCC) Average ROE

How has CYCC ROE performed in the past?

The current ROE of Cyclacel Pharmaceuticals, Inc. (CYCC) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-1301.06%

5-year avg

-799.10%

10-year avg

-432.57%

Cyclacel Pharmaceuticals, Inc. (CYCC) ROE vs. Peers

How is CYCC’s ROE compared to its peers?

Cyclacel Pharmaceuticals, Inc.’s ROE is less than Eliem Therapeutics, Inc. (0%), greater than Ikena Oncology, Inc. (-39.59%), greater than Ovid Therapeutics Inc. (-39.24%), greater than Connect Biopharma Holdings Limited (7.21%), greater than Edgewise Therapeutics, Inc. (-26.83%), greater than Rezolute, Inc. (-69.83%), greater than Cyteir Therapeutics, Inc. (-9.44%), greater than XOMA Corporation (-33.68%), greater than Protagenic Therapeutics, Inc. (-308.96%), greater than Tempest Therapeutics, Inc. (-187.44%), less than OncoVista Innovative Therapies, Inc. (0%), less than Neurobiological Technologies, Inc. (0%), less than Polydex Pharmaceuticals Limited (0%), greater than Catalyst Biosciences, Inc. (-53.04%), greater than Moleculin Biotech, Inc. (-63.14%), greater than Pulmatrix, Inc. (-165.56%), greater than Akari Therapeutics, Plc (-63.07%), less than NextCure, Inc. (550.78%), greater than CytomX Therapeutics, Inc. (-62.50%), greater than Neoleukin Therapeutics, Inc. (-41.34%), greater than Spero Therapeutics, Inc. (-8.54%), greater than Assembly Biosciences, Inc. (3.36%), greater than null (-121.46%),

Build a custom stock screener for Cyclacel Pharmaceuticals, Inc. (CYCC) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cyclacel Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Cyclacel Pharmaceuticals, Inc. (CYCC) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Cyclacel Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the ROE?

How can you use the ROE?

What is Cyclacel Pharmaceuticals, Inc.'s ROE?

How is the ROE calculated for Cyclacel Pharmaceuticals, Inc. (CYCC)?

What is the highest ROE for Cyclacel Pharmaceuticals, Inc. (CYCC)?

What is the 3-year average ROE for Cyclacel Pharmaceuticals, Inc. (CYCC)?

What is the 5-year average ROE for Cyclacel Pharmaceuticals, Inc. (CYCC)?

How does the current ROE for Cyclacel Pharmaceuticals, Inc. (CYCC) compare to its historical average?